Maze Therapeutics to Present Data from MZE829 and MZE782 Programs at ASN Kidney Week 2026
Globe Newswire•06/10/2026•16:05 ET
0
Key Highlights
- ➤Maze to present updated Phase 2 HORIZON data for MZE829 at ASN Kidney Week
- ➤MZE829 targets APOL1-mediated kidney disease in an oral October 24 presentation
- ➤Two preclinical posters support SLC6A19 inhibition for chronic kidney disease
- ➤MZE782 is in Phase 2 development for PKU and chronic kidney disease
Expert Statements
Jason Coloma, Ph.D., Chief executive officer of Maze Therapeutics
“ASN Kidney Week is an important opportunity to engage with the nephrology community and highlight the progress we are making across our kidney disease portfolio”
Jason Coloma, Ph.D., Chief executive officer of Maze Therapeutics
“We look forward to presenting the initial HORIZON results for MZE829 that we reported earlier this year, which demonstrated encouraging clinical activity in patients with AMKD.”
Jason Coloma, Ph.D., Chief executive officer of Maze Therapeutics
“Together with the preclinical research supporting MZE782, these presentations underscore our commitment to advancing new precision medicines for patients with kidney disease.”
Oral presentation will highlight previously reported Phase 2 HORIZON data for MZE829 in patients with APOL1-mediated kidney disease
Two poster presentations will highlight preclinical research supporting the therapeutic potential of SLC6A19 inhibition in chronic kidney disease
Get started
Create a free account to read the full story.